Efectividad, seguridad y aceptabilidad del tratamiento con teriflunomida en pacientes con esclerosis múltiple recurrente-remitente en el Hospital Universitario Central de Asturias (Oviedo) que iniciaron tratamiento en 2015
[EN]Introduction: Teriflunomide is an oral disease-modifying drug approved for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). It was included in the formulary of Principado de Asturias in 2015 without specific recommendations. Objective: To evaluate the effectiveness,...
| Autores: | , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2018 |
| País: | España |
| Recursos: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/136103 |
| Acesso em linha: | http://hdl.handle.net/10366/136103 |
| Access Level: | acceso abierto |
| Palavra-chave: | Teriflunomida esclerosis múltiple recurrente-remitente efectividad seguridad aceptabilidad Teriflunomide relapsing-remitting multiple sclerosis effectiveness safety acceptability |
| Resumo: | [EN]Introduction: Teriflunomide is an oral disease-modifying drug approved for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). It was included in the formulary of Principado de Asturias in 2015 without specific recommendations. Objective: To evaluate the effectiveness, safety and acceptability of teriflunomide in patients with RRMS who started treatment at Hospital Universitario Central de Asturias (HUCA) in 2015. Material and methods: Observational retrospective study of patients diagnosed with RRMS who started treatment with teriflunomide at HUCA in 2015. Results: 33 patients were included, 60,6% male with a median age of 39. Median pretreatment EDSS score was 2,5 and post treatment was 2,0. One patient experienced relapses. Hair loss, gastrointestinal disorders, fatigue and elevated liver enzymes were most common adverse events observed. Acceptability and quality of life were assessed by patients included as good-very good-excellent. Discussion: Despitethe differences between the patients included in the clinical trials and in this study, the results were similar in effectiveness and safety. Conclusions: Teriflunomide was effective and the adverse events experienced were similar to those observed in the clinical trials. The treatment was well tolerated and accepted by the patients. |
|---|